PUBLICATIONS AND PresentationS
Discover the main highlights of our industry in our latest publications.
Quick links
Presentation
Publication
Key Economic & Value Considerations in the US
Market for PPTs
Market for PPTs
Key Economic & Value Considerations for PDMPs
in Europe
in Europe
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Dec 1, 2025
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products (PDMPs) Across Europe
Against the backdrop of ongoing EU-level initiatives to improve the availability of critical medicines and strengthen supply chain resilience, this study aimed to map the overall PDMP policy landscape and key access dimensions, including reimbursement coverage, cost-containment measures, and stockpiling policies across Europe.
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/692dc8aeef30fe0ee32993ed_Understanding%20Reimbursement%20and%20Access%20Policies%20for%20Immunoglobulins%20Across%20Europe.pdf
Dec 1, 2025
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products (PDMPs) Across Europe
Against the backdrop of ongoing EU-level initiatives to improve the availability of critical medicines and strengthen supply chain resilience, this study aimed to map the overall PDMP policy landscape and key access dimensions, including reimbursement coverage, cost-containment measures, and stockpiling policies across Europe.
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/692dc8aeef30fe0ee32993ed_Understanding%20Reimbursement%20and%20Access%20Policies%20for%20Immunoglobulins%20Across%20Europe.pdf
Apr 9, 2025
Who are US Source Plasma donors? Results from a preliminary analysis
All
Publication
Apr 9, 2025
Who are US Source Plasma donors? Results from a preliminary analysis
All
Publication
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
No results found